Adam V. Patterson

6.7k citations

154 papers · 5.2k indexed · h-index 41

Co-authors: Jeff B. Smaill William R. Wilson Ian J. Stratford Christopher P. Guise Adrian L. Harris Gabi U. Dachs Alexandra M. Mowday William A. Denny
Topics: Cancer, Hypoxia, and Metabolism (64 papers)Cancer Research and Treatments (35 papers)Virus-based gene therapy research (21 papers)
Cited by: Cancer Research Biotechnology Toxicology
Journals: Journal of the American Chemical Society Journal of Biological Chemistry Nature Medicine
Partner nations: New Zealand United Kingdom China

In The Last Decade

Adam V. Patterson

153 papers receiving 5.0k citations

Peers

Countries citing papers authored by Adam V. Patterson

Since Specialization

Citations

This map shows the geographic impact of Adam V. Patterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam V. Patterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam V. Patterson more than expected).

Fields of papers citing papers by Adam V. Patterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam V. Patterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam V. Patterson. The network helps show where Adam V. Patterson may publish in the future.

Co-authorship network of co-authors of Adam V. Patterson

This figure shows the co-authorship network connecting the top 25 collaborators of Adam V. Patterson. A scholar is included among the top collaborators of Adam V. Patterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam V. Patterson. Adam V. Patterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure-Based Design of 4-(1-Methyl-1 H -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors 2026 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Xiaofei Li,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Adam V. Patterson,Jeff B. Smaill,(unknown),(unknown)	0
2	Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1H-indole-3-yl)-5H-pyrrolo[2,3-b]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance 2025 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Yan Ling,(unknown),Xiaojuan Song,Zhang Lin,Xiaofei Li,(unknown),Junping Pei,(unknown),Adam V. Patterson,Jeff B. Smaill,Bingsheng Li,Zhengchao Tu,Yang Zhou,Yongheng Chen,Xiaoyun Lu	1
3	Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells 2022 ·Journal of Medicinal Chemistry ·Fang Xu,Xin Zhang,Zhipeng Chen,Sheng He,(unknown),(unknown),Yongjin Wang,(unknown),(unknown),(unknown),Jeff B. Smaill,Adam V. Patterson,Zhimin Zhang,Liang Chen,Xiaomei Ren,Ke Ding	28
4	Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications 2022 ·Pharmaceuticals ·Amir Ashoorzadeh,Alexandra M. Mowday,Christopher P. Guise,Shevan Silva,(unknown),Maria R. Abbattista,Janine N. Copp,Elsie M. Williams,David F. Ackerley,Adam V. Patterson,Jeff B. Smaill	3
5	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors 2021 ·Journal of Medicinal Chemistry ·Xiaoyun Lu,Jeff B. Smaill,Adam V. Patterson,Ke Ding	91
6	Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors 2021 ·ACS Medicinal Chemistry Letters ·(unknown),Xiaojuan Chen,(unknown),Xiaojuan Song,Minhao Huang,Zhengchao Tu,Zhang Zhang,(unknown),Raquel Ortega,Adam V. Patterson,Jeff B. Smaill,Ke Ding,Suming Chen,Yongheng Chen,Xiaoyun Lu	14
7	Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4 2019 ·ACS Medicinal Chemistry Letters ·(unknown),Y. Yosaatmadja,(unknown),Martin Middleditch,Zhen Zhang,Xiaoyun Lu,Ke Ding,Adam V. Patterson,Jeff B. Smaill,C.J. Squire	22
8	Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects 2018 ·Journal of Medicinal Chemistry ·Xiaoyun Lu,(unknown),Adam V. Patterson,Jeff B. Smaill,Ke Ding	60
9	2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors 2017 ·ACS Medicinal Chemistry Letters ·(unknown),Zhang Zhang,Christopher P. Guise,Xueqiang Li,Jinfeng Luo,Zhengchao Tu,Yong Xu,Adam V. Patterson,Jeff B. Smaill,Xiaomei Ren,Xiaoyun Lu,Ke Ding	34
10	Identification of one-electron reductases that activate both the hypoxia prodrug SN30000 and diagnostic probe EF5 2014 ·Biochemical Pharmacology ·Jingli Wang,Christopher P. Guise,Gabi U. Dachs,Yen Phung,(unknown),Neil Lambie,Adam V. Patterson,William R. Wilson	29
11	Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy 2013 ·Molecular Cancer ·Laura K. Green,Sophie P. Syddall,(unknown),(unknown),Christopher P. Guise,Alexandra M. Mowday,Michael P. Hay,(unknown),Adam V. Patterson,David F. Ackerley	15
12	Zinc Finger Nuclease Knock-out of NADPH:Cytochrome P450 Oxidoreductase (POR) in Human Tumor Cell Lines Demonstrates That Hypoxia-activated Prodrugs Differ in POR Dependence 2013 ·Journal of Biological Chemistry ·(unknown),Yongchuan Gu,Frederik B. Pruijn,Jeff B. Smaill,Adam V. Patterson,Christopher P. Guise,William R. Wilson	18
13	Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 2011 ·Molecular Cancer Therapeutics ·Fanying Meng,James Evans,(unknown),Monica Banica,Lingyun Lan,Gustavo Lorente,Jianxin Duan,Xiaohong Cai,Alexandra M. Mowday,Christopher P. Guise,Andrej Maroz,Robert F. Anderson,Adam V. Patterson,Gregory C. Stachelek,Peter M. Glazer,Mark D. Matteucci,Charles P. Hart	160
14	The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3 2010 ·Cancer Research ·Christopher P. Guise,Maria R. Abbattista,Rachelle S. Singleton,(unknown),(unknown),Gabi U. Dachs,Stephen B. Fox,Robert Pollock,(unknown),Parry Guilford,Fernando Doñate,William R. Wilson,Adam V. Patterson	141
15	Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N 3 DNA minor groove alkylators 2009 ·Molecular Cancer Therapeutics ·William R. Wilson,Stephen M. Stribbling,Frederik B. Pruijn,Sophie P. Syddall,Adam V. Patterson,H.D. Sarath Liyanage,Eileen Smith,(unknown),Moana Tercel	29
16	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A 2009 ·Molecular Cancer Therapeutics ·Yongchuan Gu,Adam V. Patterson,Graham J. Atwell,Sophia B. Chernikova,Jeremy Brown,Larry H. Thompson,William R. Wilson	52
17	DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity 2009 ·Cancer Research ·Rachelle S. Singleton,Christopher P. Guise,Dianne M. Ferry,Susan M. Pullen,Mary J. Dorie,Jeremy Brown,Adam V. Patterson,William R. Wilson	60
18	Optimized Clostridium -Directed Enzyme Prodrug Therapy Improves the Antitumor Activity of the Novel DNA Cross-Linking Agent PR-104 2008 ·Cancer Research ·(unknown),G‐One Ahn,Mitomu Kioi,(unknown),Adam V. Patterson,J. Martin Brown	53
19	Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator 2006 ·Biochemical Pharmacology ·G‐One Ahn,(unknown),Adam V. Patterson,David C. Ware,Moana Tercel,William R. Wilson	67
20	Prodrugs in Genetic Chemoradiotherapy 2003 ·Current Pharmaceutical Design ·Adam V. Patterson,Mark Saunders,Olga Greco	36

About Adam V. Patterson

Adam V. Patterson is a scholar working on Cancer Research, Biotechnology and Toxicology, having authored 154 papers that have together received 5.2k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (64 papers), Cancer Research and Treatments (35 papers) and Virus-based gene therapy research (21 papers). The work is most often cited by research in Cancer Research (1.8k citations), Biotechnology (849 citations) and Toxicology (159 citations). Adam V. Patterson has collaborated with scholars based in New Zealand, United Kingdom and China. Frequent co-authors include Jeff B. Smaill, William R. Wilson, Ian J. Stratford, Christopher P. Guise, Adrian L. Harris, Gabi U. Dachs, Alexandra M. Mowday, William A. Denny, Ke Ding and David F. Ackerley. Their work appears in journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact